CNC

Humana (HUM) reported 25% YoY premium growth in H1 2026 driven by Medicare Advantage membership expansion, with Insurance and CenterWell segments growing 24.5% and 21.2% respectively. However, the company faces headwinds from a 180 basis point increase in benefit ratio to 90.2% and a 26.1% surge in operating expenses. Competitors Elevance Health and Centene are also navigating challenges with elevated medical costs and declining government-sponsored membership.

UnitedHealth Group is prioritizing Chronic Special Needs Plans (C-SNPs) and Dual Eligible Special Needs Plans (D-SNPs) for 2027 to drive targeted Medicare Advantage growth. UNH expects Medicare margins near the upper end of its 2%-4% target in 2026, with at least 69% of its Medicare Advantage members in four-star or higher rated plans. The company faces competition from Humana and Centene, which are also expanding specialized Medicare Advantage offerings.

Centene Corporation will launch its National Performance-Based Gold Card Program nationwide in November 2026, covering over 160,000 providers and allowing qualifying providers to bypass prior authorization for eligible outpatient services. The initiative aims to reduce administrative burden and processing costs while maintaining clinical oversight. Centene trades at 13.13x forward earnings with 2026 EPS estimated to grow 135.1% to $4.89, though the stock carries a Zacks Rank #4 (Sell) rating.